{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:53Z","timestamp":1792783253231,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"IL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monitoring for the anticoagulant effect of unfractionated (UFH) at the point of care using activated clotting time in real time is vital where risk of thrombosis is high. Although monitoring UFH effect is a routine and important task, changing from one ACT instrument type or technology to another must be preceded by a clinical and statistical evaluation to determine the suitability and repeatability and establish normal and treatable ranges of this newer instrument. In this multi-center prospective evaluation we tested 1236 paired ACT+\u2009samples, and 463 paired ACT-LR samples (1699 total) from enrolled study subjects. Clinical settings included CVOR cardiopulmonary bypass, at the beside in extracorporeal life support (ELS), the Cardiac Catheterization Lab (CCL) during diagnostic studies and percutaneous coronary interventions (PCI), interventional radiology procedures and EP interventions. This study found more consistent clinical performance from the GEM Hemochron 100 as compared to the current clinical model, the Hemochron Signature Elite. The bias of GEM Hemochron 100 for ACT+\u2009and ACT-LR was greatest in the setting of the CVOR where ACT levels were high. ACT-LR measurements by the GEM Hemochron 100 were comparable to the SE when performed in settings of CCL, ECM, EP and ICU. Results obtained for both ACT-LR and ACT+\u2009in all clinical settings in this study using the GEM Hemochron 100 are as accurate and more repeatable as those with the current clinically available Signature Elite.<\/jats:p>","DOI":"10.1007\/s11239-022-02672-y","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T11:18:59Z","timestamp":1655896739000},"page":"660-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Activated clotting time in inpatient diagnostic and interventional settings"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9443-3533","authenticated-orcid":false,"given":"Heidi","family":"Dalton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7806-8038","authenticated-orcid":false,"given":"Michael","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5987-9775","authenticated-orcid":false,"given":"Pamela","family":"Garcia-Filion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shavelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Hsiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Beinart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole","family":"Korpi-Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"issue":"5","key":"2672_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0022-5223(19)41500-6","volume":"69","author":"BS Bull","year":"1975","unstructured":"Bull BS, Huse WM, Brauer FS, Korpman RA (1975) UFH therapy during extracorporeal circulation II. The use of a dose\u2013response curve to individualize UFH and protamine dosage. J Thorac Cardiovasc Surg 69(5):685\u2013689","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"2672_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0022-5223(19)41499-2","volume":"69","author":"BS Bull","year":"1975","unstructured":"Bull BS, Korpman RA, Huse WM, Briggs BD (1975) UFH therapy during extracorporeal circulation: I. Problems inherent in existing UFH protocols. J Thorac Cardiovasc Surg 69(5):674\u2013684","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"2672_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.hoc.2016.06.002","volume":"30","author":"RI Handin","year":"2016","unstructured":"Handin RI (2016) The history of antithrombotic therapy: the discovery of UFH, the Vitamin K antagonists, and the utility of aspirin. Hematol Oncol Clin N Am 30(5):987\u2013993. https:\/\/doi.org\/10.1016\/j.hoc.2016.06.002","journal-title":"Hematol Oncol Clin N Am"},{"issue":"2","key":"2672_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1213\/ANE.0000000000002613","volume":"126","author":"L Shore-Lesserson","year":"2018","unstructured":"Shore-Lesserson L, Baker RA, Ferraris VA et al (2018) The society of thoracic surgeons, the society of cardiovascular anesthesiologists, and the american society of extracorporeal technology: clinical practice guidelines anticoagulation during cardiopulmonary bypass. Anesth Analg 126(2):413\u2013424","journal-title":"Anesth Analg"},{"issue":"7","key":"2672_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/17474086.2017.1345306","volume":"10","author":"I Baluwala","year":"2017","unstructured":"Baluwala I, Favaloro EJ, Pasalic L (2017) Therapeutic monitoring of unfractionated UFH\u2014trials and tribulations. Expert Rev Hematol 10(7):595\u2013605. https:\/\/doi.org\/10.1080\/17474086.2017.1345306","journal-title":"Expert Rev Hematol"},{"key":"2672_CR6","doi-asserted-by":"publisher","unstructured":"Penk JS, Reddy S, Polito A, Cisco MJ, Allan CK, Bembea M, Giglia TM, Cheng HH, Thiagarajan RR, Dalton HJ (2019) Bleeding and thrombosis with pediatric extracorporeal life support: a roadmap for management, research, and the future from the pediatric cardiac intensive care society: part 2. Pediatr Crit Care Med. 20(11):1034\u20131039. https:\/\/doi.org\/10.1097\/PCC.0000000000002054","DOI":"10.1097\/PCC.0000000000002054"},{"key":"2672_CR7","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1111\/jth.12963","volume":"13","author":"GM Annich","year":"2015","unstructured":"Annich GM (2015) Extracorporeal life support: the precarious balance of hemostasis. J Thromb Haemost 13:S336\u2013S342. https:\/\/doi.org\/10.1111\/jth.12963","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2672_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/ject-1900024","volume":"51","author":"S Kitchen","year":"2019","unstructured":"Kitchen S, Geisen U, Kappelmayer J, Quehenberger P, Lowe A, Jones R, Miles Matte GS, Howe RJ, Ibla J, Emani S, Emani SM (2019) Transition from Hemochron response to hemochron signature elite activated clotting time devices in a congenital cardiac surgery practice. J Extra Corpor Technol 51(4):221\u2013226. https:\/\/doi.org\/10.1182\/ject-1900024","journal-title":"J Extra Corpor Technol"},{"issue":"3","key":"2672_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/bja\/aet384","volume":"112","author":"T Gauss","year":"2014","unstructured":"Gauss T, Hamada S, Jurcisin I, Dahmani S, Boudaoud L, Mantz J, Paugam-Burtz C (2014) Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron signature elite(R) during acute haemorrhage. Br J Anaesth 112(3):514\u2013520. https:\/\/doi.org\/10.1093\/bja\/aet384","journal-title":"Br J Anaesth"},{"issue":"6","key":"2672_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/ijlh.12896","volume":"40","author":"JG Boehm","year":"2018","unstructured":"Boehm JG, Rozsnyai G. (2018) Evaluating the analytical performance of four new coagulation assays for the measurement of fibrinogen, D-dimer and thrombin time. Int J Lab Hematol 40(6):637\u2013644. https:\/\/doi.org\/10.1111\/ijlh.12896","journal-title":"Int J Lab Hematol"},{"key":"2672_CR11","unstructured":"EP09-A3Measurement procedure comparison and bias estimation using patient samples; approved guideline\u2014Third Edition"},{"issue":"8","key":"2672_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","volume":"110","author":"SJ Brener","year":"2004","unstructured":"Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ (2004) Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 110(8):994\u2013998. https:\/\/doi.org\/10.1161\/01.CIR.0000139868.53594.24","journal-title":"Circulation"},{"issue":"7\u20138","key":"2672_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1345\/aph.1E524","volume":"39","author":"SA Spinler","year":"2005","unstructured":"Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA (2005) Anticoagulation monitoring part 2: unfractionated UFH and low-molecular-weight UFH. Ann Pharmacother 39(7\u20138):1275\u20131285. https:\/\/doi.org\/10.1345\/aph.1E524","journal-title":"Ann Pharmacother"},{"key":"2672_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivw435","author":"A Vries","year":"2017","unstructured":"Vries A, Lansink-Hartgring A, Fernhout F-J, Huet R, den Heuvel V, Edwin. (2017) The activated clotting time in cardiac surgery: should celite or kaolin be used? Interact Cardiovasc Thorac Surg. https:\/\/doi.org\/10.1093\/icvts\/ivw435","journal-title":"Interact Cardiovasc Thorac Surg"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-022-02672-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T05:11:39Z","timestamp":1667106699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-022-02672-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2672"],"URL":"https:\/\/doi.org\/10.1007\/s11239-022-02672-y","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"26 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors and co-authors state that they have the following disclosures. Michael Martin was employed by Werfen as the Senior Manager of Clinical Affairs during the clinical conduct of this study and is no longer employed by Werfen. Pamela Garcia-Filion was paid a consulting fee for the statistical analyses included in this manuscript. Except as noted above the authors and co-authors state that they have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}